Research groups
Peter Kok-Ting Wan
BSc, MPhil, DPhil
Postdoctoral researcher
- Lecturer of MSc in Experimental and Translational Therapeutics
- Tutor of MSc in Applied Cancer Science
Cancer immunotherapy, tumour microenvironment, translational science
Research summary
My research focuses on addressing the critical challenges posed by the tumour microenvironment, which plays a pivotal role in cancer progression, immune evasion, and therapeutic resistance. I am working on developing novel strategies to target the tumour microenvironment with the aim of improving treatment outcomes.
Translational science lies at the core of these efforts, bridging the gap between laboratory discoveries and clinical applications. By leveraging human-derived samples, including primary ascites and freshly resected solid biopsies, I have developed several advanced preclinical models to validate therapeutic approaches in clinically relevant settings.
My research integrates bioinformatics, immunotherapy, and oncolytic virotherapy to create more effective treatments for solid cancers. This includes engineering bispecific antibodies to remodel the immunosuppressive tumour microenvironment. These efforts aim to accelerate the transition of promising therapies from the bench to the bedside.
Recent publications
-
Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
Baugh R. et al, (2024), J Immunother Cancer, 12
-
Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?
Wan PK-T. et al, (2023), J Immunother Cancer, 11
-
Beyond cancer cells: Targeting the tumor microenvironment with gene therapy and armed oncolytic virus.
Wan PK-T. et al, (2021), Mol Ther, 29, 1668 - 1682
-
HPV-induced Nurr1 promotes cancer aggressiveness, self-renewal, and radioresistance via ERK and AKT signaling in cervical cancer.
Wan PK-T. et al, (2021), Cancer Lett, 497, 14 - 27
-
Role of Nurr1 in Carcinogenesis and Tumor Immunology: A State of the Art Review.
Wan PK-T. et al, (2020), Cancers (Basel), 12